GEORGE DAOUD

• Lead and execute GCC market access strategy for Rare Disease Unit (RDU) portfolios, aligning local execution with global access guidance and regional priorities.
• Secure reimbursement, pricing approvals, and formulary inclusion for ultra–high-cost therapies across public and semi‑government healthcare systems.
• Drive payer ecosystem mapping and engagement across ministries of health, HTA bodies, payer committees, and funding authorities.
• Translate global health economic models (cost‑effectiveness, budget impact) into locally relevant payer value narratives aligned with GCC HTA expectations.
• Develop and submit robust reimbursement and HTA dossiers supporting early access and long‑term coverage sustainability.
• Design and implement Early Access Programs (EAPs) and Patient Support Programs (PSPs) in compliance with local regulations and FM‑aligned ethical standards.
• Monitor healthcare policy, regulatory, and reimbursement landscape changes and proactively adapt access strategies accordingly.
• Collaborate closely with Medical, Regulatory, Finance, Supply Chain, and Commercial teams to overcome access barriers and optimize launch readiness.

Key Achievements:

• Achieved full government enlistment for Daybue® (Trofinetide) for Rett Syndrome in UAE and Qatar, ongoing access expansion across Kuwait, Oman, and Bahrain.
• Generated USD 3.345M in turnover within 7 months through accelerated access enablement and payer negotiations.
• Effectively navigated the newly implemented DOH classified patient-specific approval pathway, enabling rapid and uninterrupted patient access.

• Led pricing, reimbursement, and access strategy for specialty and rare disease therapies across GCC markets.
• Secured formulary inclusion and reimbursement for Voraxaze® (Glucarpidase) and Cyanokit® (Hydroxocobalamin), generating over €1.6M in revenue.
• Managed tender submissions, contract negotiations, demand forecasting, and stock allocation to ensure uninterrupted patient access.
• Partnered with payer committees, hospital procurement, and government funding bodies to establish sustainable reimbursement pathways.
• Localized EMA evidence packages and supported real‑world evidence generation aligned with regional payer requirements.
• Collaborated cross‑functionally to support launch excellence and lifecycle management initiatives.

• Supported market access and KOL engagement for Eylea® (Aflibercept) across public and private institutions.
• Achieved 72.8% national market share, positioning Eylea as market leader in retinal therapies in the UAE.
• Supported pricing strategy, formulary submissions, and payer negotiations in collaboration with regulatory and tendering teams.
• Successfully launched Eylea® in Oman, securing rapid adoption through targeted stakeholder engagement.
• Collaborated with healthcare professionals to identify patient needs and tailor product offerings accordingly.
• Conducted comprehensive market analysis to inform product positioning and competitive strategies.
• Trained and mentored junior staff on product features and clinical applications to enhance team capabilities.
• Facilitated the creation of promotional materials and campaigns to effectively communicate product benefits to target audiences.

• Managed pricing, reimbursement, and access for Betaferon® (interferon beta-1b) for (Multiple Sclerosis) and Ventavis® (Iloprost) for (Pulmonary Arterial Hypertension) across three GCC markets.
• Successfully launched Adempas® (Riociguat) for Pulmonary Arterial Hypertension in Kuwait, Bahrain & Qatar, securing market access, reimbursement alignment, and stakeholder adoption within government and institutional settings.
• Partnered with government funding bodies (e.g., Kuwait Patient Helping Fund) to secure sustainable patient affordability pathways.
• Led cross-functional collaboration to support regional market expansion and medical education initiatives.
• Developed and maintained relationships with key opinion leaders and healthcare providers.